The estimated Net Worth of Paul Marshall is at least 3.98 千$ dollars as of 21 March 2016. Paul Marshall owns over 1,100 units of Heron Therapeutics Inc stock worth over 3,982$ and over the last 10 years Paul sold HRTX stock worth over 0$.
Sign up
Paul Marshall HRTX stock SEC Form 4 insiders trading
Paul has made over 4 trades of the Heron Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Paul exercised 1,100 units of HRTX stock worth 9,955$ on 21 March 2016.
The largest trade Paul's ever made was exercising 70,000 units of Heron Therapeutics Inc stock on 5 March 2015 worth over 658,000$. On average, Paul trades about 12,217 units every 64 days since 2014. As of 21 March 2016 Paul still owns at least 2,200 units of Heron Therapeutics Inc stock.
You can see the complete history of Paul Marshall stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Paul Marshall's mailing address?
Paul's mailing address filed with the SEC is 123 SAGINAW DRIVE, , REDWOOD CITY, CA, 94063.
Insiders trading at Heron Therapeutics Inc
Over the last 11 years, insiders at Heron Therapeutics Inc have traded over 96,663,574$ worth of Heron Therapeutics Inc stock and bought 6,549,746 units worth 56,275,132$ . The most active insiders traders include Kevin Ctang Capital Managem...、Adam Morgan、Craig A Collard. On average, Heron Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 176,989$. The most recent stock trade was executed by Craig A Collard on 19 July 2024, trading 13,797 units of HRTX stock currently worth 24,973$.
What does Heron Therapeutics Inc do?
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
What does Heron Therapeutics Inc's logo look like?
Complete history of Paul Marshall stock trades at Heron Therapeutics Inc
Heron Therapeutics Inc executives and stock owners
Heron Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Barry Quart,
Chairman of the Board, Chief Executive Officer -
John Poyhonen,
President and Chief Commercial Officer -
Kimberly Manhard,
Executive Vice President - Drug Development, Director -
Dr. Barry D. Quart,
Chairman & CEO -
Kimberly J. Manhard,
Exec. VP of Drug Devel. & Director -
John W. Poyhonen,
Pres & Chief Commercial Officer -
David L. Szekeres,
Exec. VP & COO -
Stephen Davis,
Independent Director -
Craig Johnson,
Lead Independent Director -
Christian Waage,
Independent Director -
Lisa Peraza,
Chief Accounting Officer, Vice President -
John Arthur,
Vice President - Manufacturing and Supply -
Sean Ristine,
Vice President - Human Resources -
Christopher Storgard,
Chief Medical Officer -
Thomas Ottoboni,
Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer -
Michael Mathews,
Senior Vice President - Pain Franchise -
Anita Gupta,
Senior Vice President - Medical Strategy and Government Affairs -
David Szekeres,
Chief Operating Officer, Executive Vice President -
Dr. Chris M. Storgard,
Chief Medical Officer -
Michael E. Mathews,
Sr. VP of Acute Care -
Dr. Thomas B. Ottoboni,
Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences -
Sean T. Ristine,
Sr. VP of HR -
Sharmila Dissanaike,
Director -
Paul Marshall,
SVP, Technical Operations -
Robert Rosen,
President -
Kevin Ctang Capital Managem...,
-
Brian G. Drazba,
VP, Finance & CFO -
Robert Hoffman,
CFO & SVP, Finance -
Kevin C Tang,
Director -
Mark S. Md Gelder,
SVP & Chief Medical Officer -
Neil James Clendeninn,
SVP & Chief Medical Officer -
Susan Rodriguez,
Director -
Adam Morgan,
Director -
Craig A Collard,
Chief Executive Officer -
William P Forbes,
EVP, Chief Development Officer -
Ira Duarte,
EVP, Chief Financial Officer